Clinical Trial

CAR-T Cell Efficacy With Molecular Imaging in Multiple Myeloma

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
⁶⁸Ga-NOTA-BCMA is a novel, targeted PET tracer under clinical investigation. It is designed to provide a non-invasive method for monitoring the biodistribution and persistence of BCMA CAR-T cells in patients. Preclinical data robustly support its specific binding, favorable pharmacokinetics, and excellent safety profile, warranting its advancement into clinical studies.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-09.
Trial Details
NCT Number NCT07280793
Lead Sponsor Xuzhou Medical University
Conditions Non-invasive CAR-T Cell Monitoring, BCMA-targeted PET Imaging, CAR-T Cell Biodistribution and Persistence, GMP-compliant Radiopharmaceutical Preparation
Enrollment 10 participants
Start Date 2025-12-17
Primary Completion 2027-12-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-17